HIMS

HIMS

USD

Hims & Hers Health Inc. Class A Common Stock

$44.070-1.680 (-3.672%)

Real-time Price

Healthcare
Drug Manufacturers - Specialty & Generic
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$45.750

High

$48.340

Low

$43.620

Volume

36.16M

Company Fundamentals

Market Cap

10.0B

Industry

Drug Manufacturers - Specialty & Generic

Country

United States

Trading Stats

Avg Volume

28.91M

Exchange

NYQ

Currency

USD

52-Week Range

Low $19.15Current $44.070High $72.98

Related News

Analyst Upgrades

B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $32

B of A Securities analyst Allen Lutz maintains Hims & Hers Health with a Underperform and raises the price target from $28 to $32.

View more
B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $32
Reuters

Futures tumble after Wall St banks warn of market pullback, Palantir slides

U.S. stock futures tumbled on Tuesday as investors questioned lofty valuations in the technology sector after top Wall Street banks warned of a stock market selloff and AI darling Palantir's sales forecast failed to lift the mood.

View more
Futures tumble after Wall St banks warn of market pullback, Palantir slides
Analyst Upgrades

BTIG Reiterates Buy on Hims & Hers Health, Maintains $85 Price Target

BTIG analyst David Larsen reiterates Hims & Hers Health with a Buy and maintains $85 price target.

View more
BTIG Reiterates Buy on Hims & Hers Health, Maintains $85 Price Target
Reuters

Hims and Hers beats revenue estimates on strong subscriber growth

Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added subscribers and expanded its personalized healthcare offerings.

View more
Hims and Hers beats revenue estimates on strong subscriber growth
BusinessWire

Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results

Revenue of nearly $600 million, up 49% year-over-year in Q3 2025 Net income of nearly $16 million; Adjusted EBITDA of over $78 million in Q3 2025 Subscribers grew to almost 2.5 million, up 21% year-over-year in Q3

View more
Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results
PR Newswire

LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc.

A securities fraud class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) is pending. The lawsuit was filed by Glancy Prongay & Murray...

Analyst Upgrades

Keybanc Initiates Coverage On Hims & Hers Health with Sector Weight Rating

Keybanc analyst Justin Patterson initiates coverage on Hims & Hers Health with a Sector Weight rating.